Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

Visit Project Website Go back to Experience
Coordinating Center
Emmes U.S.
Project Status
Active
Project Lifespan
08/31/2013
Objective

The primary aim of the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) is to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with CRVO, with the primary outcome of visual acuity measured at 6 months.

Population

Participants with macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) who are 18 years of age or older and are willing to provide consent are eligible for SCORE2.

Phase
III
Centers

Eighty (80) clinical centers across the continental U.S.

Products
AdvantageEDC
Regulatory Tracking System
Services
Data Analysis and Reporting
Independent Data and Safety Monitoring Board Services
Medical Monitoring
Meeting Coordination and Support
Protocol Monitoring
Project Management
Regulatory Affairs
Site Selection and Contracting
Statistical Leadership and Project Management
Study Design/Protocol Development
Subject Recruitment
Training and Certification
Web-based Data Collection and Reporting Systems
Ophthalmology